The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.

During the past decade, partnerships were the most frequent type of deal in North America and Asia-Pacific. Meanwhile, in Europe, mergers and licensing agreements contributed to an equal number of ...

One thing that sticks with me is how earnest the documentary feels. Steen was both a dear and considerate friend to the ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ( ARWR ...

This Friday, November 29, the Spirit of Christmas concert returns to Belfast for a sixth year to raise money for Muscular ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Columnist Patrick Moeschen, who lives with limb-girdle muscular dystrophy, explains why controlling what he can is so ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

Additionally, Sarepta’s expertise in Duchenne Muscular Dystrophy (DMD), coupled with its extensive patient, payer, and prescriber network, reinforces its market leadership. The company’s gene therapy ...

A small trial of an experimental vaccine has shown promising results for patients with the most aggressive type of breast ...

A small trial of an experimental vaccine has shown promising results for patients with the most aggressive type of breast ...